Invest Policy
No Result
View All Result
Friday, March 5, 2021
  • Login
  • Latest News
  • Banking
  • Economy
  • Market
  • Investment Plans
    • Mutual Funds
    • Money
    • Property
    • Scheme
  • Finance
  • Insurance
    • General Insurance
    • Life Insurance
    • LIC
  • World
Subscribe
Invest Policy
  • Latest News
  • Banking
  • Economy
  • Market
  • Investment Plans
    • Mutual Funds
    • Money
    • Property
    • Scheme
  • Finance
  • Insurance
    • General Insurance
    • Life Insurance
    • LIC
  • World
No Result
View All Result
Invest Policy
No Result
View All Result
Home Latest News

Serum will send vaccine to 25-30 countries today

by InvestPolicy
February 28, 2021
in Latest News
0
152
SHARES
1.9k
VIEWS
Share on FacebookShare on Twitter

The first batch of AstraZeneca-Oxford vaccines prepared by the Serum Institute of India (SII) to protect against coronaviruses will be sent to 25–30 countries by Tuesday. This information has been given by a senior official of the World Health Organization (WHO).

WHO Chief Scientist Soumya Swaminathan said in a webinar on Monday that from Monday or Tuesday, the first batch of vaccines from India will be sent to 25-30 countries which have been prepared by the Serum Institute and after that we hope that the other ones will be made in the country. Vaccines will be sent in a similar way.

Encouraging the spirit of extending the vaccine to the needy in their country as well as abroad, Swaminathan said that vaccine manufacturers need to prioritize the WHO-led Kovacs initiative for a bilateral agreement with various countries aimed at And safe, effective and equitable distribution of vaccines even to middle-income countries. He said, “Today we are seeing more bilateral agreements being made than vaccines being supplied to Kovacs.”

Serum Institute Chief Executive (CEO) Adar Poonawalla tweeted on Sunday, ‘Many countries and governments that are waiting for the supply of Kovishield, I humbly request you to please be patient, give the serum institute a vaccine in India Besides giving priority to wider needs, it has also been directed to balance with the needs of the rest of the world. We are doing our best for this.

Thus Swaminathan also emphasized that high, medium and low income countries also need to follow the rules as the Kovacs initiative will only be cleared if access to resources should not be hampered by prioritizing country distribution and They should not impose export restrictions.

Meanwhile, Bharat Biotech President and Managing Director Krishna Alla also said that he is eager to join Kovacs. He said, ‘We are already supplying many vaccines like Typhoid conjugate and Rotavirus to UNICEF. We want to be part of the WHO-led Kovacs soon. We would like to join Kovacs as soon as we release the third phase impact data. ‘ He said that Bharat Biotech is also keen to work with the WHO on intra-nasal vaccines and on this the company wants to move fast. This week the clinical trial of the first phase of this vaccine will be started.

Ella feels that the vaccine distribution is slightly decentralized and unorganized at the moment. He says, ‘Every country is trying to procure vaccines. Though this entire system is still unorganized but once there is sufficient supply it will become more organized. In the next 5-6 months, I expect that vaccine delivery efforts will be more organized worldwide.

Swaminathan pointed out that the WHO-led Kovacs already has a $ 2.3 billion funding gap for 2021. At the same time, the difference of funding for Kovid-19 Tools Accelerator or STC Accelerator should be $ 23 billion or more. ACT Accelerator is a G20 countries initiative announced in April 2020 calling for global collaboration for the treatment, screening, vaccine development, production and equitable delivery of Kovid-19. Kovacs is the vaccine pillar of the ACT Accelerator.

Covaxin effect data in two weeks

Krishna Alla, president and managing director of Bharat Biotech, said that they would release data related to the third phase of covicin in two weeks. In a webinar, Alla said the company had combined Phase II and Phase III studies and data related to its impact may be available soon. The indigenous vaccine formulated by Bharat Biotech and the Indian Council of Medical Research (ICMR) has received approval from the Indian drug regulator for vaccination of healthcare personnel and frontline personnel under clinical trials. The regulator’s approval of restricted emergency use was based on data from Phase II safety and immunity-based studies as well as tests conducted on the monkey.

Alla also said that the intra-nasal vaccine is also set to begin the first phase of testing this week.

  • Trending
  • Comments
  • Latest
MP E Uparjan

MP E Uparjan 2021 | Farmer online registration, mpeuparjan.nic.in portal

February 27, 2021
What is the role of two employees of Wipro in wrong transfer of Rs 6554 crore to Citibank

What is the role of two employees of Wipro in wrong transfer of Rs 6554 crore to Citibank

February 26, 2021
sukanya-samriddhi-yojana-vs-lic-kanyadan-policy

LIC Kanyadan Policy Vs Sukanya Samriddhi Yojana

March 2, 2021
Amazon's logo was being trolled by saying Hitler's face, the company made changes once again after seeing opposition

Amazon’s logo was being trolled as Hitler’s face, the company made changes once again after seeing protest

March 1, 2021
RailTel IPO: Premium falls in gray market, should you still invest?

Nureca’s IPO will open for subscription on February 15, should it subscribe or not? Know the opinion of experts

February 28, 2021
Anurag Kashyap and Taapsee Pannu may face difficulties, fearing manipulation of Rs 650 crore

Anurag Kashyap and Taapsee Pannu may face difficulties, fearing manipulation of Rs 650 crore

March 4, 2021
YES Bank stocks rise for the third consecutive day, know what is the opinion of brokerage on YES Bank

Yes Bank Stocks: Despite the steep decline in the stock market and the Bank Index, there has been a sharp rise in the stocks of Yes Bank, now what next?

March 4, 2021
Gainers Losers: These 10 stocks were the biggest stir today

Gainers Losers: These 10 stocks were the biggest stir today

March 4, 2021
Feeling like May in March, heat coming ahead of time, what are the remedies to escape!

Feeling like May in March, heat coming ahead of time, what are the remedies to escape!

March 4, 2021
Value and thematic funds once again in focus, should you invest?

Value and thematic funds once again in focus, should you invest?

March 4, 2021

Recent News

Anurag Kashyap and Taapsee Pannu may face difficulties, fearing manipulation of Rs 650 crore

Anurag Kashyap and Taapsee Pannu may face difficulties, fearing manipulation of Rs 650 crore

March 4, 2021
YES Bank stocks rise for the third consecutive day, know what is the opinion of brokerage on YES Bank

Yes Bank Stocks: Despite the steep decline in the stock market and the Bank Index, there has been a sharp rise in the stocks of Yes Bank, now what next?

March 4, 2021

Categories

  • Banking
  • Economy
  • Featured
  • Finance
  • General Insurance
  • Health Insurance
  • Insurance
  • Investment Plans
  • Latest News
  • LIC
  • Life Insurance
  • Market
  • Money
  • Mutual Funds
  • Property
  • Scheme
  • World

Site Navigation

  • Home
  • Advertisement
  • Contact Us
  • Privacy & Policy
  • Other Links
Invest Policy

InvestPolicy.com is one of the leading companies when it comes to loans and card marketplace. Our main motto is to help our customers in making personal finance decisions easy and convenient as per their comfort.

© 2021 Invest Policy. All Right Reserved.

No Result
View All Result
  • Latest News
  • Banking
  • Economy
  • Market
  • Investment Plans
    • Mutual Funds
    • Money
    • Property
    • Scheme
  • Finance
  • Insurance
    • General Insurance
    • Life Insurance
    • LIC
  • World
  • About Us
  • Contact Us

© 2021 Invest Policy. All Right Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In